4:15 PM Development of EVER001, a Covalent Reversible Bruton’s Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Primary Membranous Nephropathy and Other Rare Kidney Diseases
Time: 4:15 pm
day: Conference Day 1
Details:
- Outlining the role of BTK in modulating B-cell pathways that are involved in the pathogenesis of autoimmune kidney diseases
- Reviewing the current clinical data demonstrating the activity of EVER001 in primary membranous nephropathy
- Looking towards expanded applications in additional rare, immune-mediated kidney disorders
